SCHEMBL3669340

SCHEMBL3669340

CCC(CC)n1c(O)nc2nccc(C(=O)O)c21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5B Q9UGL1 5/20 0.37
KDM4E B2RXH2 5/20 0.36
ASPH Q12797 4/20 0.36
KDM8 Q8N371 4/20 0.36
KDM4A O75164 1/20 0.35
RAB9A P51151 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35
HIF1AN Q9NWT6 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MAPT P10636 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
KDM5A P29375 4/20 0.33
MAPK8 P45983 2/20 0.33
FABP4 P15090 2/20 0.31
HCAR3 P49019 1/20 0.31
NR4A3 Q92570 1/20 0.31
KDM6B O15054 1/20 0.31
KDM4C Q9H3R0 1/20 0.31
GABRP O00591 1/20 0.31
GABRD O14764 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3669343 0.74 ALDH1A1 (0.40) KDM4EKDM4ARAB9AEGLN1HIF1AN
SCHEMBL3665285 0.70 KMT2A (0.39) RAB9A
SCHEMBL1667424 0.68 DHODH (0.40) KDM5BKDM4EASPHKDM8KDM4A
SCHEMBL3671068 0.68 HCAR3 (0.41) L3MBTL1MAPTHCAR3
SCHEMBL3672336 0.67 HRH4 (0.34)
SCHEMBL3669198 0.67 HTR2A (0.33)
SCHEMBL13007715 0.66 CYP1A2 (0.36)
SCHEMBL3776790 0.66 TDP1 (0.30) TDP1
SCHEMBL2301190 0.66 CTSA (0.36) KDM4EL3MBTL1MAPK8
SCHEMBL3668551 0.64

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851484-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2010-12-14 US claimed
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods CYTOKINETICS, INC. 2008-10-02 US claimed
US-7851484-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2010-12-14 US disclosed
US-7851484-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2010-12-14 US disclosed
EP-2139478-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS Cytokinetics, Incorporated (US) 2010-01-06 EP disclosed
WO-2008121333-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED (US) 2008-10-09 WO disclosed
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods CYTOKINETICS, INC. 2008-10-02 US disclosed
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods CYTOKINETICS, INC. 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods TNNC1, TNNI3, TNNT2 KDM5B 4232/4885KDM4E 4360/4885ASPH 4268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.